MedPath

Clinical Trial News

Oncolytic Virus Therapy Emerges as Promising Cancer Treatment Breakthrough

  • Oncolytic virus therapy shows remarkable potential in cancer treatment by selectively targeting and destroying cancer cells while activating immune responses, marking a significant advancement in immunotherapy.
  • Recent clinical trials demonstrate that combining oncolytic viruses with checkpoint inhibitors, such as Amgen's Imlygic with Keytruda, achieved a 62% response rate in melanoma patients.
  • Major pharmaceutical companies are heavily investing in oncolytic virus platforms, with Janssen's $1 billion acquisition of BeneVir BioPharm and Merck's $400 million purchase of Viralytics highlighting industry confidence.

Advancing Precision Medicine with Synthetic Nearest Neighbors in Clinical Trials

A novel approach using Synthetic Nearest Neighbors (SNN) estimator to predict patient-level outcomes from population-level randomized control trials (RCTs) has shown promising results, particularly in Alzheimer’s Disease research. This method addresses the challenges of missing data and patient heterogeneity, offering a pathway towards personalized medicine.

CHMP Backs Novel Therapies: Onpattro for hATTR and Symkevi for Cystic Fibrosis

• The European Medicines Agency's CHMP has recommended approval for Alnylam's Onpattro (patisiran), a groundbreaking siRNA therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
• Vertex's Symkevi (tezacaftor/ivacaftor), in combination with Kalydeco, received positive CHMP opinion for treating cystic fibrosis patients with specific F508del mutations.
• The committee also endorsed several other medications, including Pierre Fabre's melanoma drugs and AstraZeneca's Imfinzi for lung cancer, while rejecting BMS's Opdivo-Yervoy combination for first-line kidney cancer.

Sanofi Establishes €66 Million Global R&D Hub in Chengdu, Expanding China Research Footprint

  • Sanofi is investing €66 million to establish a new global research hub in Chengdu, China, focusing on data analysis and management of multi-center clinical trials.
  • The facility aims to recruit 300 R&D staff by 2020 and will support research across multiple therapeutic areas including diabetes, cardiovascular diseases, oncology, and rare diseases.
  • This expansion establishes China as Sanofi's third major research pillar alongside France and the US, building upon their existing R&D presence in Shanghai.

Genetic Variants and Their Impact on Clinical Responses to Treatments

Recent studies have explored the relationship between genetic variants and clinical responses to various treatments, including mesalamine for ulcerative colitis, ALK inhibitors for non-small cell lung cancer, and metformin for type 2 diabetes. Findings suggest that while some genetic variants do not significantly affect treatment outcomes, others may influence drug efficacy and patient survival.

Vedolizumab: A New Therapeutic Option for Inflammatory Bowel Disease

Vedolizumab, a fully humanised monoclonal antibody, has emerged as a promising treatment for patients with moderate-to-severe ulcerative colitis and Crohn’s disease who are refractory or intolerant to conventional treatments or anti-TNFα agents. This article reviews the efficacy, safety, and tolerability of vedolizumab, highlighting its role in the treatment algorithms for inflammatory bowel disease based on clinical trials and real-world studies.

Pfizer, Amgen, and Sanofi Partner to Leverage Blockchain Technology in Clinical Trials

  • Three pharmaceutical giants - Pfizer, Amgen, and Sanofi - have joined forces to explore blockchain technology's potential in enhancing data management and reducing drug development costs in clinical trials.
  • Blockchain technology offers a secure, immutable platform for storing clinical trial data, addressing critical challenges in patient privacy, data integrity, and efficient information sharing across multiple databases.
  • Research indicates only 16% of patients are aware of relevant clinical trials, highlighting the potential for blockchain to revolutionize patient recruitment and trial participation through anonymous data sharing and smart contracts.

Rising Demand for Comparator Clinical Trials Reshapes Drug Development Landscape

  • Comparator clinical trials are experiencing increased demand driven by market competition, regulatory pressure, and the growing complexity of therapeutic protocols.
  • Supply chain challenges in comparator studies, including product sourcing and logistics, significantly impact trial timelines and require careful planning and risk management.
  • The shift towards comparator trials over placebo-controlled studies is motivated by ethical considerations and regulatory preferences, particularly in evaluating new drugs against existing treatments.

First Immunotherapy Success in Prostate Cancer Shows Promise for DNA Repair-Deficient Tumors

Precision Medicine
  • A landmark clinical trial demonstrates that pembrolizumab immunotherapy provides survival benefits for a subset of men with advanced, otherwise untreatable prostate cancer.
  • Of 258 men treated with pembrolizumab, 38% remained alive after one year and 11% continued treatment without disease progression.
  • Men with DNA repair gene mutations in their tumors showed higher response rates, suggesting genetic testing could identify optimal candidates for immunotherapy.
  • Researchers are planning a new trial specifically targeting prostate cancer patients with DNA repair mutations to validate this precision medicine approach.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.